DE-CSC
CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division that reveals areas of risk for prominent election-related websites. The research indicates that web domains closely linked to the campaign websites for Joe Biden and Donald Trump lack basic domain security protocols and are being targeted for disinformation activities such as domain spoofing, and threats including domain name and domain name system (DNS) hijacking, and phishing.
On the heels of its recent Forbes Global 2000 research , CSC is seeing major risks related to the manipulation of web properties that voters rely on for information and donations. Findings show that over 90% of these web properties are not using registry locks to protect their domains from domain and DNS hijacking that can lead to phishing attacks, network breaches, and email compromise.
“As noted in our previous research, we’ve consistently seen domains emerge as a threat vector for enterprises, and an area that is continuously overlooked in cyber security. Due to the sensitivity and importance of the U.S. election process, domain security remains a major vulnerability for the potential of foreign interference, fraud, and misinformation,” says Mark Calandra, executive vice president for CSC DBS. “As an organization with the most visibility into the domain landscape, we advocate for the sanctity of voter trust and encourage both presidential candidates and other websites in the electoral ecosystem to prioritize domain security on their websites to ensure security and build confidence.”
"We have reached the point where awareness is not enough. Those responsible for managing domain registrations, including registrars and hosting companies, need to have an actionable plan that is aligned with best practices. Additionally, experiences must be shared between those within the industry for the good of the wider internet community," said Matthew Stith, industry liaison at Spamhaus. “Without this commitment, users will be open to continued manipulation and fraud."
In April of 2020 when domain names were at the center of many COVID-19 related fraud schemes, Senators Mazie K. Hirono (D-Hawaii), Cory Booker (D-N.J.), and Maggie Hassan (D-N.H.) called on domain name registrars and hosting sites to combat scams and misinformation. CSC’s research shows that domain security and preventing domain spoofing continue to be an oversight even with top election-related web properties. Our research shows that more than 75% of these election-related domains are using retail-grade domain registrars, which do not provide advanced security protocols.
Our research also showed that, of the typo domains related to joebiden.com and donaldjtrump.com , 60% are still available for registration, thereby posing future threats. Additionally, more than a third of those presidential candidate typo domains are linked to third parties; of that one third, nearly 70%:
- Are configured to send and receive emails, which can be used to lure donors to phishing sites
- Were registered in 2020 leading up to the November election
- Disguise the owner’s identity behind proxy or privacy services
With cyber criminals subverting activities on these websites to disseminate misinformation or commit fraud against web visitors, there is also the threat of ransomware. Simon Chassar, chief revenue officer at NTT Ltd.’s Security division states, "NTT's September Monthly Threat Report identified ransomware as a significant threat to the U.S. election infrastructure. With DNS, domains, and email being a potential vehicle to distribute malicious content, our NTT Ltd. Security division suggests focus in this area, ensuring it is secure by design."
For additional details on these findings, visit the CSC blog “U.S. Election-Related Web Properties Prone to Fraud and Misinformation Due to Lack of Domain Security.”
Note: CSC aggregated this data using SimilarWeb.com for the period of August 1 – August 30, 2020.
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005203/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
